505486 | Pramipexole Dihydrochloride - CAS 104632-25-9 - Calbiochem

505486
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₁₀H₁₇N₃S•2HCl 104632-25-9

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      5.05486.0001
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 10 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewNon-ergot Dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9 nM for D3, D2S, D2L and D4 receptors respectively). Exhibits very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Shows good solubility in aqueous media (100 mM water and 100 mM DMSO). Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinsons disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
          Catalogue Number505486
          Brand Family Calbiochem®
          SynonymsPramipexole, Dopamine D2-like Receptor Agonist, Pramipexole, Dopamine D3 Receptor Agonist, Pramipexole, (S)-Nʹ-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride
          References
          ReferencesAntonini, A. 2011. Expert Op. Drug Metabol. Tox. 7, 1307.
          Collins, G. T. et al. 2008. J. Pharmacol. 325, 691.
          Product Information
          CAS number104632-25-9
          FormWhite solid
          Hill FormulaC₁₀H₁₇N₃S•2HCl
          Chemical formulaC₁₀H₁₇N₃S•2HCl
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetD3
          Primary Target K<sub>i</sub>0.5 nM
          Purity≥99% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          References

          Reference overview
          Antonini, A. 2011. Expert Op. Drug Metabol. Tox. 7, 1307.
          Collins, G. T. et al. 2008. J. Pharmacol. 325, 691.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision30-August-2013 JSW
          SynonymsPramipexole, Dopamine D2-like Receptor Agonist, Pramipexole, Dopamine D3 Receptor Agonist, Pramipexole, (S)-Nʹ-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride
          DescriptionNon-ergot Dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9 nM for D3, D2S, D2L and D4 receptors respectively). Exhibits very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Shows good solubility in aqueous media (100 mM water and 100 mM DMSO). Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinsons disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
          FormWhite solid
          CAS number104632-25-9
          Chemical formulaC₁₀H₁₇N₃S•2HCl
          Structure formulaStructure formula
          Purity≥99% by HPLC
          SolubilityH₂O (100 mM)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesAntonini, A. 2011. Expert Op. Drug Metabol. Tox. 7, 1307.
          Collins, G. T. et al. 2008. J. Pharmacol. 325, 691.